- Home
- CRBP vs MMLP Comparison
CRBP vs MMLP Comparison
Compare CRBP & MMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- MMLP
- Stock Information
- Founded
- CRBP 2009
- MMLP 2002
- Country
- CRBP United States
- MMLP United States
- Employees
- CRBP N/A
- MMLP N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- MMLP Oil Refining/Marketing
- Sector
- CRBP Health Care
- MMLP Energy
- Exchange
- CRBP Nasdaq
- MMLP Nasdaq
- Market Cap
- CRBP 143.7M
- MMLP 140.8M
- IPO Year
- CRBP N/A
- MMLP 2002
- Fundamental
- Price
- CRBP $11.93
- MMLP $3.64
- Analyst Decision
- CRBP Strong Buy
- MMLP
- Analyst Count
- CRBP 8
- MMLP 0
- Target Price
- CRBP $62.00
- MMLP N/A
- AVG Volume (30 Days)
- CRBP 256.8K
- MMLP 179.2K
- Earning Date
- CRBP 03-11-2025
- MMLP 02-12-2025
- Dividend Yield
- CRBP N/A
- MMLP 0.55%
- EPS Growth
- CRBP N/A
- MMLP N/A
- EPS
- CRBP N/A
- MMLP 0.11
- Revenue
- CRBP N/A
- MMLP $717,396,000.00
- Revenue This Year
- CRBP N/A
- MMLP N/A
- Revenue Next Year
- CRBP N/A
- MMLP $0.80
- P/E Ratio
- CRBP N/A
- MMLP $33.30
- Revenue Growth
- CRBP N/A
- MMLP N/A
- 52 Week Low
- CRBP $7.30
- MMLP $2.04
- 52 Week High
- CRBP $61.90
- MMLP $4.13
- Technical
- Relative Strength Index (RSI)
- CRBP 39.08
- MMLP 49.77
- Support Level
- CRBP $11.02
- MMLP $3.17
- Resistance Level
- CRBP $13.28
- MMLP $3.70
- Average True Range (ATR)
- CRBP 0.74
- MMLP 0.19
- MACD
- CRBP 0.16
- MMLP 0.03
- Stochastic Oscillator
- CRBP 40.27
- MMLP 80.60
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About MMLP Martin Midstream Partners L.P. Limited Partnership
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.